A. S. Starovoitova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
A. S. Starovoitova has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- A. A. Fedorenko
Almazov National Medical Research Center
1 shared publication - A. A. Moskalev
Ministry of Health of the Russian Federation
1 shared publication - Aleksey N. Yakovlev
Almazov National Medical Research Center
1 shared publication - Alexey Aleksandrovich Maschan
The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Health of the Russian Federation
1 shared publication - Anzhela Soloveva
Almazov National Medical Research Center
1 shared publication - E. A. Medvedeva
Almazov National Medical Research Centre
1 shared publication
Latest Publications
- Open Access
- 8 August 2025
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 30 (6) , 6391
Preferential drug program for patients within the federal project for control of cardiovascular diseases: implementation strategy, results and prospects
A serious barrier to the widespread practical implementation of evidence therapy for cardiovascular diseases is financial constraints, which exacerbate low patient complience and affect inequality in cardiovascular health indicators population, increasing morbidity and mortality. At the level of healthcare systems in different countries, drug provision is recognized as an effective tool for increasing patient adherence to treatment and improving clinical outcomes. The problematic article discusses the preferential drug program within the federal project for control of cardiovascular diseases. The key principles for forming priority groups, mechanisms and stages of program implementation are outlined. Monitoring the program’s effectiveness made it possible to identify reserves and prospects for its further strategic development.
- 8 August 2025
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 30 (6) , 6391
Open AccessPreferential drug program for patients within the federal project for control of cardiovascular diseases: implementation strategy, results and prospects
A serious barrier to the widespread practical implementation of evidence therapy for cardiovascular diseases is financial constraints, which exacerbate low patient complience and affect inequality in cardiovascular health indicators population, increasing morbidity and mortality. At the level of healthcare systems in different countries, drug provision is recognized as an effective tool for increasing patient adherence to treatment and improving clinical outcomes. The problematic article discusses the preferential drug program within the federal project for control of cardiovascular diseases. The key principles for forming priority groups, mechanisms and stages of program implementation are outlined. Monitoring the program’s effectiveness made it possible to identify reserves and prospects for its further strategic development.
- Open Access
- 9 November 2017
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 16 (4)
Childhood acute myeloid leukemia with the t(8;16)(p11;p13) translocation
Acute myeloid leukemia is a clonal systemic disease of the hematologic system, which includes heterogeneous group of diseases. Therefore optimization of methods of treatment of this pathology is an important task. More than 1% of AML with rare translocations can not be strictly divided into risk groups. There are also discrepancies between different researchers’ data on the same cytogenetic abnormalities. In this article we present the experience of diagnostics and therapy of the patient with the rare sub-type of AML with the t(8;16)(p11;p13) translocation in Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology. The patient received high-dose chemotherapy and allogeneic hematopoietic stem cell transplant. According to catamnesis the child (1.5 years) has been in the clinico-hematological and cytogenetic remission.
- 9 November 2017
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 16 (4)
Open AccessChildhood acute myeloid leukemia with the t(8;16)(p11;p13) translocation
Acute myeloid leukemia is a clonal systemic disease of the hematologic system, which includes heterogeneous group of diseases. Therefore optimization of methods of treatment of this pathology is an important task. More than 1% of AML with rare translocations can not be strictly divided into risk groups. There are also discrepancies between different researchers’ data on the same cytogenetic abnormalities. In this article we present the experience of diagnostics and therapy of the patient with the rare sub-type of AML with the t(8;16)(p11;p13) translocation in Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology. The patient received high-dose chemotherapy and allogeneic hematopoietic stem cell transplant. According to catamnesis the child (1.5 years) has been in the clinico-hematological and cytogenetic remission.